Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 439.17 Billion JPY | -22.06% |
| 2022 | 533.3 Billion JPY | 26.41% |
| 2021 | 421.89 Billion JPY | 40.06% |
| 2020 | 301.23 Billion JPY | 43.04% |
| 2019 | 210.59 Billion JPY | 69.4% |
| 2018 | 124.32 Billion JPY | 25.66% |
| 2017 | 98.93 Billion JPY | 28.68% |
| 2016 | 76.88 Billion JPY | -11.41% |
| 2015 | 86.78 Billion JPY | 14.4% |
| 2014 | 75.85 Billion JPY | -3.66% |
| 2013 | 78.73 Billion JPY | 3.04% |
| 2012 | 76.41 Billion JPY | -29.14% |
| 2011 | 107.84 Billion JPY | 62.81% |
| 2010 | 66.23 Billion JPY | -19.82% |
| 2009 | 82.61 Billion JPY | 60.22% |
| 2008 | 51.56 Billion JPY | -22.7% |
| 2007 | 66.7 Billion JPY | 14.32% |
| 2006 | 58.34 Billion JPY | -26.3% |
| 2005 | 79.16 Billion JPY | 53.73% |
| 2004 | 51.49 Billion JPY | 20.55% |
| 2003 | 42.71 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 101.55 Billion JPY | -11.18% |
| 2024 Q2 | 159.71 Billion JPY | 55.9% |
| 2023 Q3 | 106.68 Billion JPY | -5.26% |
| 2023 Q4 | 114.33 Billion JPY | 7.17% |
| 2023 Q1 | 98.29 Billion JPY | -34.24% |
| 2023 FY | 415.66 Billion JPY | -22.06% |
| 2023 Q2 | 112.61 Billion JPY | 14.57% |
| 2022 Q4 | 149.47 Billion JPY | 54.28% |
| 2022 Q2 | 99.94 Billion JPY | -46.56% |
| 2022 Q1 | 187 Billion JPY | 34.48% |
| 2022 FY | 533.3 Billion JPY | 26.41% |
| 2022 Q3 | 96.88 Billion JPY | -3.05% |
| 2021 Q2 | 96.71 Billion JPY | 51.19% |
| 2021 Q1 | 63.96 Billion JPY | -13.46% |
| 2021 FY | 421.89 Billion JPY | 40.06% |
| 2021 Q4 | 139.06 Billion JPY | 13.84% |
| 2021 Q3 | 122.15 Billion JPY | 26.31% |
| 2020 Q1 | 72.41 Billion JPY | 45.64% |
| 2020 Q3 | 86.69 Billion JPY | 27.08% |
| 2020 FY | 301.23 Billion JPY | 43.04% |
| 2020 Q4 | 73.91 Billion JPY | -14.74% |
| 2020 Q2 | 68.21 Billion JPY | -5.79% |
| 2019 Q3 | 65.82 Billion JPY | 34.45% |
| 2019 Q2 | 48.95 Billion JPY | 6.21% |
| 2019 FY | 210.59 Billion JPY | 69.4% |
| 2019 Q1 | 46.09 Billion JPY | 74.53% |
| 2019 Q4 | 49.71 Billion JPY | -24.47% |
| 2018 Q3 | 31.34 Billion JPY | 11.12% |
| 2018 Q4 | 26.41 Billion JPY | -15.74% |
| 2018 Q2 | 28.2 Billion JPY | -26.47% |
| 2018 Q1 | 38.36 Billion JPY | 68.99% |
| 2018 FY | 124.32 Billion JPY | 25.66% |
| 2017 Q4 | 22.7 Billion JPY | -22.08% |
| 2017 Q2 | 20.75 Billion JPY | -21.21% |
| 2017 Q1 | 26.34 Billion JPY | 44.36% |
| 2017 FY | 98.93 Billion JPY | 28.68% |
| 2017 Q3 | 29.13 Billion JPY | 40.35% |
| 2016 FY | 76.88 Billion JPY | -11.41% |
| 2016 Q3 | 15.12 Billion JPY | -35.54% |
| 2016 Q2 | 23.46 Billion JPY | 16.99% |
| 2016 Q1 | 20.05 Billion JPY | 1.66% |
| 2016 Q4 | 18.24 Billion JPY | 20.68% |
| 2015 FY | 86.78 Billion JPY | 14.4% |
| 2015 Q4 | 19.72 Billion JPY | -17.29% |
| 2015 Q3 | 23.84 Billion JPY | 6.18% |
| 2015 Q2 | 22.46 Billion JPY | 8.24% |
| 2015 Q1 | 20.75 Billion JPY | 24.07% |
| 2014 Q3 | 16.01 Billion JPY | 33.15% |
| 2014 Q4 | 16.72 Billion JPY | 4.42% |
| 2014 FY | 75.85 Billion JPY | -3.66% |
| 2014 Q1 | 31.08 Billion JPY | 51.08% |
| 2014 Q2 | 12.02 Billion JPY | -61.31% |
| 2013 Q4 | 20.57 Billion JPY | 2.68% |
| 2013 Q3 | 20.04 Billion JPY | -14.56% |
| 2013 FY | 78.73 Billion JPY | 3.04% |
| 2013 Q1 | 14.66 Billion JPY | -47.97% |
| 2013 Q2 | 23.45 Billion JPY | 59.97% |
| 2012 FY | 76.41 Billion JPY | -29.14% |
| 2012 Q1 | 16.61 Billion JPY | -31.24% |
| 2012 Q4 | 28.18 Billion JPY | 102.73% |
| 2012 Q3 | 13.9 Billion JPY | -21.52% |
| 2012 Q2 | 17.71 Billion JPY | 6.61% |
| 2011 Q4 | 24.16 Billion JPY | 63.05% |
| 2011 FY | 107.84 Billion JPY | 62.81% |
| 2011 Q3 | 14.82 Billion JPY | -24.49% |
| 2011 Q1 | 15.56 Billion JPY | -26.27% |
| 2011 Q2 | 19.62 Billion JPY | 26.11% |
| 2010 Q4 | 21.1 Billion JPY | 20.16% |
| 2010 Q2 | 16.48 Billion JPY | 48.79% |
| 2010 Q1 | 11.07 Billion JPY | -53.51% |
| 2010 FY | 66.23 Billion JPY | -19.82% |
| 2010 Q3 | 17.56 Billion JPY | 6.58% |
| 2009 Q1 | 17.53 Billion JPY | 0.0% |
| 2009 Q3 | 21.6 Billion JPY | 9.99% |
| 2009 Q4 | 23.82 Billion JPY | 10.29% |
| 2009 FY | 82.61 Billion JPY | 60.22% |
| 2009 Q2 | 19.64 Billion JPY | 12.05% |
| 2008 FY | 51.56 Billion JPY | -22.7% |
| 2007 FY | 66.7 Billion JPY | 14.32% |
| 2006 FY | 58.34 Billion JPY | -26.3% |
| 2005 FY | 79.16 Billion JPY | 53.73% |
| 2004 FY | 51.49 Billion JPY | 20.55% |
| 2003 FY | 42.71 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | -5260.356% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | -2447.118% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -6159.597% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 1105440.783% |
| Novartis AG | 9.76 Billion USD | -4395.588% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 87.885% |